Haemophilia B: an illustrative review of current challenges and opportunities

Hemophilia B is a genetic bleeding disorder caused by a deficiency of clotting factor IX, which presents unique challenges in clinical management. Advances in therapeutic strategies for hemophilia B have significantly improved patient outcomes but have also necessitated ongoing education for healthcare professionals. This illustrated review provides an overview of the challenges and opportunities in hemophilia B care, including best practice management, emerging therapies, and remaining research needs.

To provide a comprehensive visual summary of contemporary perspectives on hemophilia B pathophysiology and management through an illustrated review.

The authors, leveraging their clinical experience and expertise in hemophilia B management, conducted a review of relevant articles in PubMed (Supplementary Methods).

The review is divided into illustrated sections that provide an overview of hemophilia B, detailing its clinical manifestations, hemostatic agents, and treatment challenges. It also examines the pharmacokinetic properties of hemophilia B and the importance of individualized treatment approaches.

This illustrated review educates healthcare professionals on hemophilia B management in the current treatment landscape, empowering them to further disseminate knowledge to both their colleagues and patients.